Sandoz is the generic division of Novartis and the acquisiton of Fougera will reside within this division it appears. The two companies already service some of the same accounts. BD
Novartis is buying specialty dermatology generics firm Fougera Pharmaceuticals for $1.525 billion in cash. The Swiss drug 
giant says adding Fougera to its Sandoz generics business will transform the latter into the world’s biggest generic dermatology medicines operation, with estimated annual global sales approaching $620 million.
“
The addition of Fougera’s leading portfolio further strengthens Sandoz’ differentiated products strategy,” comments Jeff George, global head of Sandoz. “Fougera brings us valuable technical capabilities in the area of topical dermatology products, particularly in the development and manufacturing of semisolid forms such as creams and ointments.”
http://www.genengnews.com/gen-news-highlights/novartis-to-buy-dermatology-generics-firm-fougera-for-1-525b-cash/81246720/
![EZClaim[4]](http://lh4.ggpht.com/_v3zjJigoAPE/TG1-9etl5ZI/AAAAAAAAgqg/CRMlet5Pi5k/EZClaim44.png?imgmax=800 "EZClaim[4]")
Math–This Could be a Subject for Michael Moore to Explore and Document In a Movie
Screenings Too–Killer Algorithms Part 12–Medical Billing Codes Style
Assessing Consumer Credit Scores–Attack of the Killer Algorithms Chapter 21 With Flawed Data
Duping” Society Combined With A World of Rogue Algorithms & Flawed Data Continues In Markets As Seen With Knight Capital This Week-Attack of the Killer Algorithms Chapter 36
Study Fraud With EHR Technologies, Namely Medical Records/Billing Software Used by Hospitals– HHS And SEC Continue Getting Their Non-Algorithmic Fannies Kicked–Attack of the Killer Algorithms Chapter 46
SilverScript Senior Drug Program Sanctioned by Medicare Until the Payment And Billing Algorithms are Cleaned Up-Killer Algorithms Chapter 53
